Linking <i>in vitro–in vivo</i> extrapolations with physiologically based modeling to inform drug and formulation development-Reference-Cited by-同舟云学术

Linking in vitro–in vivo extrapolations with physiologically based modeling to inform drug and formulation development

Published:2023-08 Issue:4 Volume:44 Page:289-291
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm & Drug Disp

Author:

Cristofoletti Rodrigo¹,Rostami‐Hodjegan Amin²³^ORCID

Affiliation:

1. Department of Pharmaceutics Center for Pharmacometrics and Systems Pharmacology College of Pharmacy University of Florida Orlando Florida USA

2. Centre for Applied Pharmacokinetic Research University of Manchester Manchester UK

3. Certara UK Limited Sheffield UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bdd.2375

Reference25 articles.

1. In‐depth analysis of patterns in selection of different physiologically‐based pharmacokinetic modeling tools: Part II — Assessment of model reusability and comparison between open and non‐open source‐code software

2. In vitro–in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human

3. Harnessing the power of physiologically based pharmacokinetic modeling to explore potential discordance between in vitro dissolution, local gut vs systemic bioequivalence in health and disease: The case of budesonide in Crohn’s disease;Chunyan Han T. S.;Pharmaceutics,2023

4. Integrating Drug- and Formulation-Related Properties With Gastrointestinal Tract Variability Using a Product-Specific Particle Size Approach: Case Example Ibuprofen